Cargando…

ALK gene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinoma

OBJECTIVE: The relationship between anaplastic lymphoma kinase (ALK) expression in malignant pleural effusion (MPE) samples detected only by Ventana immunohistochemistry (IHC) ALK (D5F3) and the efficacy of ALK-tyrosine kinase inhibitor therapy is uncertain. METHODS: Ventana anti-ALK (D5F3) rabbit m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zheng, Wu, Xiaonan, Han, Xiaohong, Cheng, Gang, Mu, Xinlin, Zhang, Yuhui, Cui, Di, Liu, Chang, Liu, Dongge, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242450/ https://www.ncbi.nlm.nih.gov/pubmed/28174489 http://dx.doi.org/10.21147/j.issn.1000-9604.2016.06.07

Ejemplares similares

A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
por: Tachi, Hiroaki, et al.
Publicado: (2020)

Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative
por: Ma, Di, et al.
Publicado: (2016)

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC
por: Wang, Shasha, et al.
Publicado: (2022)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Detection of EML4-ALK in Lung Adenocarcinoma Using Pleural Effusion with FISH, IHC, and RT-PCR Methods
por: Liu, Leilei, et al.
Publicado: (2015)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy
por: Mönch, Dina, et al.
Publicado: (2018)

Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
por: Zhang, Xiangming, et al.
Publicado: (2023)

ALK-positive anaplastic large cell lymphoma that presented as pleural effusion
por: Kim, Do Hwan, et al.
Publicado: (2022)

Case Report: Long-term remission of malignant pleural and peritoneal effusion in a case of advanced lung adenocarcinoma treated with combined crizotinib and anlotinib therapy
por: Tian, Jin, et al.
Publicado: (2023)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
por: Cui, Shaohua, et al.
Publicado: (2016)

Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma
por: Zhang, Ping, et al.
Publicado: (2019)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report
por: Yang, Yanlong, et al.
Publicado: (2022)

Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib
por: Xu, Chun-wei, et al.
Publicado: (2018)

Variations in pleural microbiota and metabolic phenotype associated with malignant pleural effusion in human lung adenocarcinoma
por: Huang, DanHui, et al.
Publicado: (2023)

Primary peritoneal adenocarcinoma causes pleural effusion
por: Shameem, Mohammad, et al.
Publicado: (2010)

Malignant pleural effusion from prostate adenocarcinoma
por: Knight, James C., et al.
Publicado: (2014)

Lumican Is Overexpressed in Lung Adenocarcinoma Pleural Effusions
por: Cappellesso, Rocco, et al.
Publicado: (2015)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

A Novel c-Mesenchymal-Epithelial Transition Factor Intergenic Fusion Response to Crizotinib in a Chinese Patient With Lung Adenocarcinoma: A Case Report
por: Liang, Hongge, et al.
Publicado: (2021)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

The Correlation between EGFR Mutation Status and DNA Content of Lung Adenocarcinoma Cells in Pleural Effusion
por: Du, Yun, et al.
Publicado: (2020)

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma
por: Gennatas, Spyridon, et al.
Publicado: (2013)

Case Report: A Chronological Combination Treatment of Icotinib, Osimertinib, and Crizotinib on Lung Adenocarcinoma Guided by Serial Genetic Tests of Circulating Tumor DNA and Sediment Cell Genomic DNA From Pleural Effusion
por: Miao, Zhihua, et al.
Publicado: (2020)

Use of Platelet Parameters in the Differential Diagnosis of Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Tuberculous Pleural Effusion
por: Ai, Ling, et al.
Publicado: (2022)

Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion
por: Verma, Akash, et al.
Publicado: (2016)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Pleural Effusion
por: Gray, Frank D.
Publicado: (1963)

Pleural Effusion
por: Brunton, T. Lauder
Publicado: (1898)

Pleural Effusion
por: Sherding, Robert G., et al.
Publicado: (2006)

Pleural Effusions
Publicado: (1877)

Detection of ALK Gene Rearrangement in Cell-free RNA from Lung Cancer Malignant Pleural Effusion
por: Chu, Mingliang, et al.
Publicado: (2020)

Malignant Müllerian Adenocarcinoma Manifesting With Cardiac Tamponade and Pleural Effusion
por: Maaliki, Naji, et al.
Publicado: (2021)

Lung adenocarcinoma with eosinophilic pleural effusion: A case report
por: Zhou, Xiangxiang, et al.
Publicado: (2021)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Boulos, Joelle C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9btu6j0s7lmgbk5g26nfbdhre2